Gossamer Bio Inc (GOSS)
Healthcare
Biotechnology
0.17 $
-4.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Gossamer Bio Inc (GOSS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 28.2% of the shares are freely tradable; institutional investors hold 75.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
75.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
28.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
11.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
489Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Kalehua Capital Management LLC | 7.58 | 17,708,133 | +0.0 | 03/31/2026 |
| BlackRock Inc | 7.20 | 16,826,695 | -1.3 | 03/31/2026 |
| Vanguard Group Inc | 5.51 | 12,873,209 | +7.2 | 12/31/2025 |
| AQR Capital Management LLC | 4.33 | 10,126,897 | +804.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.02 | 9,394,593 | +0.0 | 03/31/2026 |
| ARCH VENTURE CORP | 3.45 | 8,055,916 | +0.0 | 03/31/2026 |
| Octagon Capital Advisors LP | 3.32 | 7,750,000 | -44.3 | 03/31/2026 |
| CI Private Wealth LLC | 3.29 | 7,691,770 | +38,347.3 | 12/31/2025 |
| Samsara BioCapital, LLC | 3.09 | 7,222,559 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.96 | 6,910,934 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.